{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Alnylam Pharmaceuticals, Inc.
Is Alnylam Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Alnylam Pharmaceuticals, Inc. shows a mildly bullish trend, supported by daily indicators, though tempered by weekly bearish signals, with a year-to-date return of 84.47% compared to the S&P 500's 16.30%.
Is Alnylam Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Alnylam Pharmaceuticals has a mildly bullish technical trend, supported by strong monthly indicators and a year-to-date return of 93.80%, significantly outperforming the S&P 500's 16.30%.
Is Alnylam Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Alnylam Pharmaceuticals has a mildly bullish technical trend, supported by monthly indicators and daily moving averages, and has outperformed the S&P 500 with a year-to-date return of 93.80% compared to 16.30%.
Alnylam Pharmaceuticals Hits Day Low of $436.51 Amid Price Pressure
Alnylam Pharmaceuticals experienced a notable decline in stock value on October 30, 2025, amid a challenging trading session. Despite recent fluctuations, the company has shown strong long-term performance, with significant gains over the past year and five years, although it faces challenges such as a net profit loss and low return on capital employed.
Alnylam Pharmaceuticals Faces Weak Start with 6.56% Gap Down Amid Market Concerns
Alnylam Pharmaceuticals, Inc. experienced a notable decline in stock performance, contrasting with the stable S&P 500. The company, valued at approximately USD 59.645 billion, faces challenges with negative return on equity and high price-to-book ratio. Technical indicators show mixed signals, reflecting a complex market environment.
Alnylam Pharmaceuticals Hits New 52-Week High of $485.28
Alnylam Pharmaceuticals, Inc. achieved a new 52-week high of USD 485.28 on October 15, 2025, reflecting its strong performance in the biotechnology sector. The company has seen substantial growth over the past year, despite being loss-making, and maintains a high price-to-book ratio and no dividend yield.
Is Alnylam Pharmaceuticals, Inc. technically bullish or bearish?
As of May 29, 2025, Alnylam Pharmaceuticals has shifted to a bullish trend with strong technical indicators, including bullish MACD and moving averages, despite a recent short-term decline, and has significantly outperformed the S&P 500 year-to-date and over five years.
Is Alnylam Pharmaceuticals, Inc. technically bullish or bearish?
As of May 29, 2025, the technical trend is bullish with strong indicators like MACD and Bollinger Bands supporting this view, although caution is advised due to a bearish monthly RSI.
Who are in the management team of Alnylam Pharmaceuticals, Inc.?
As of March 2022, the management team of Alnylam Pharmaceuticals, Inc. includes CEO Dr. John Maraganore and Independent Chairman Mr. Michael Bonney, along with several independent directors such as Dr. Margaret Hamburg and Dr. Steven Paul. This team provides governance and strategic direction for the company.
What does Alnylam Pharmaceuticals, Inc. do?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing RNA interference therapeutics, with recent net sales of $594 million and a market cap of approximately $40.25 billion. The company is currently operating at a loss, with a net profit of -$57 million.
How big is Alnylam Pharmaceuticals, Inc.?
As of Jun 18, Alnylam Pharmaceuticals, Inc. has a market capitalization of $40.25 billion, with recent net sales of $2.35 billion and a net profit of -$269.70 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
